title: The opportunity cost of androgen suppression in locally advanced prostate cancer.
authors: Harvard Radiation Oncology Program, Boston, MA 02114, USA. pjgray@partners.org
authors: Phillip J
authors: PJ
authors: Gray
authors: Jason A
authors: JA
authors: Efstathiou
authors: William U
authors: WU
authors: Shipley
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001918:Brachytherapy; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D016729:Leuprolide